OakChart

AgomAb Therapeutics NV ADR

AGMBHealthcare·Biotechnology·Belgium·Small·NASD·Nov 11 • 12:40 PM ET

6.97-0.02 (-0.29%)
2026-11-11 18:42 CET
Market cap
344.24 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-36.13 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.89
P/E
-
Compare

Price

AGMB against its 20 and 50-day averages
2050missearnings
10.0015.00390K781KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AGMBclose 6.9720-day 7.8950-day 9.896.9752w high

60.9% under the 52-week high of 17.82 on 29 Jun 2026. 52-week low 6.46 on 5 Nov 2026. Last 15 sessions, 46.1% high to low

Profile

AGMB
52-week range, 4% of the way up
6.4617.82

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

Employees62
IPOFeb 06, 2026
ATR, 14d0.83
Rel volume2.62
Short float2.53%
Insider own25.98%
Inst own27.59%

Snapshot

6 groups

Valuation

Index-
Market Cap343.27M
Enterprise Value56.48M
Income-
Sales-
Book/sh6.16
Cash/sh5.85
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees62
IPOFeb 06, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.13
P/C1.19
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio12.88
Current Ratio12.88
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-2.04
EPS next Q-0.34
EPS this Y98.91%
EPS next Y-17.49%
EPS next 5Y76.32%
EPS past 3/5Y-102.05% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsAug 06 AMC
EPS/Sales Surpr.-177.84% -

Ownership

Insider Own25.98%
Insider Trans0.48%
Inst Own27.59%
Inst Trans0.12%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-11.71%
SMA50-29.52%
SMA200-41.41%
Trades-

Technical

Shs Outstand48.74M
Shs Float36.45M
Short Float2.53%
Short Ratio5.41
Short Interest0.92M
52W High17.82 -60.89%
52W Low6.46 7.89%
Volatility12.65% 10.42%
ATR (14)0.83
RSI (14)33.57
Beta-
Rel Volume2.62
Avg Volume170.23K
Volume231,298

Performance

Perf Week1.75%
Perf Month-20.89%
Perf Quarter-50.02%
Perf Half Y-37.66%
Perf YTD-52.59%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price37.71
Prev Close6.99
Price6.97
Change %-0.29%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Aug 25, 2026InitiatedPPiper SandlerOverweight$60+760.8%
Aug 19, 2026InitiatedCCantor FitzgeraldOverweight
Jul 23, 2026InitiatedRB. Riley SecuritiesBuy$34+387.8%
Jun 22, 2026InitiatedHH.C. WainwrightBuy$35+402.2%
Mar 03, 2026InitiatedMMorgan StanleyOverweight$28+301.7%
Mar 03, 2026InitiatedLLeerink PartnersOutperform$36+416.5%
Mar 03, 2026InitiatedJJP MorganOverweight$32+359.1%

Peers

Mkt cap
TickerCompanyMkt cap
ODTXOdyssey Therapeutics Inc999.81M
SRZNSurrozen Inc612.93M
ABVXAbivax ADR8.03B
PLRXPliant Therapeutics Inc47.71M
SYRESpyre Therapeutics Inc10.03B
VCREVicore Pharma Holding AB ADR316.80M
AVLNAvalyn Pharma Inc1.38B
CLYMClimb Bio Inc714.26M
GALTGalectin Therapeutics Inc338.85M
LKFTLakefront Biotherapeutics NV ADR2.18B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Epstein David RDirectorNov 05 '26Buy6.9015,000103,50040,000Nov 06 06:39 AM
Epstein David RDirectorOct 21 '26Buy8.8810,00088,80025,000Oct 22 08:14 AM
Epstein David RDirectorOct 08 '26Buy8.905,00044,50015,000Oct 09 08:01 AM
Epstein David RDirectorOct 06 '26Buy8.705,00043,50010,000Oct 07 08:57 AM
Epstein David RDirectorOct 05 '26Buy8.575,00042,8505,000Oct 07 08:57 AM
Kemula Pierre Thadee VictorChief Financial OfficerOct 06 '26Buy8.5910,00085,94010,000Oct 07 08:47 AM
Knotnerus Tim JasperChief Executive OfficerOct 05 '26Buy8.486,00050,88016,823Oct 07 08:06 AM
Knotnerus Tim JasperChief Executive OfficerOct 06 '26Buy8.705,00043,50021,823Oct 07 08:06 AM

Held by

AUM
TickerCompanyAUM
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M

News

latest 14 of 20
  • Agomab to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire)
  • Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation (GlobeNewswire)
  • Agomab stock jumps on positive trial data (Investing.com) -22.07%
  • Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire)
  • Loading…
  • Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study (GlobeNewswire) -5.97%
  • Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors (GlobeNewswire) -6.31%
  • Agomab to Participate in Upcoming Investor Conferences (GlobeNewswire) +8.57% +6.41%
  • Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors (GlobeNewswire)
  • Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook (GlobeNewswire) -5.73% +7.41%
  • Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire) +6.20%
  • Agomab Announces Results of Annual General Meeting (GlobeNewswire) +5.61%
  • Agomab to Participate in Upcoming Conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-08-06-0.9151.176-0.8860.00-1
2026Q12026-06-03-0.402-0.427-0.3770.000.003
2025Q42026-04-23-0.561-0.517-0.4160.000.001
2026Q3---0.453--0.003
2026Q4---0.453--0.003
2026S2---0.990--0.005
2027Q1---0.472--0.001
2027Q2---0.495--0.001
2027Q3---0.507--0.001
2027Q4---0.519--0.001
2027S1---1.127--0.002
2027S2---1.209--0.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-163.5-2.317-163.040.000.71
2026FY--1.740--0.44
2027FY--2.045--0.53
2028FY--2.123--1.02
2029FY--2.364--1.43
2030FY--1.893--1.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-08-244000.000.000.00
2026S2S2026-08-123000.000.000.00
2026S2S2026-08-072000.000.000.00
2026S2R2026-08-12100-1.06-1.06-1.06
2026S2E2026-08-26500-0.99-1.14-0.77
2026S2E2026-08-24400-1.05-1.14-0.83
2026S2E2026-08-12300-1.00-1.13-0.82
2026S2E2026-08-07200-0.97-1.13-0.82
2026Q3S2026-08-072000.000.000.00
2026Q3S2026-06-182000.000.000.00
2026Q3S2026-06-031000.000.000.00
2026Q3S2026-04-241000.000.000.00
2026Q3S2026-03-021000.000.000.00
2026Q3R2026-08-08100-0.56-0.56-0.56

Estimate history

EPS, annual-0.176-0.253-1.027-1.448
Period2022202320242025
EPS, quarterly-0.257-0.416
PeriodQ4 '24Q4 '25
Sales, annual0000
Period2022202320242025
Sales, quarterly00
PeriodQ4 '24Q4 '25
Shares, annual48.73748.73748.73748.737
Period2022202320242025
Shares, quarterly48.73748.737
PeriodQ4 '24Q4 '25

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.880.250.340.110.02
Gross Profit-2.88-0.25-0.34-0.11-0.02
Selling, General and Administrative Excl. Other38.1169.3553.1534.9325.13
Research and Development26.7955.1642.5228.4520.41
Other Operating Expense0.000.000.000.000.00
Operating Income-40.99-69.60-53.48-35.04-25.15
Interest Expense0.250.080.080.040.05
Unusual Expense0.515.37-0.92-20.50-12.50
Net Income Before Taxes-36.13-71.17-50.47-13.34-11.79
Income Taxes0.00-0.58-0.43-1.03-3.23
Consolidated Net Income-36.13-70.59-50.05-12.31-8.56
Net Income From Continuing Operations-36.13-70.59-50.05-12.31-8.56
Net Income-36.13-70.59-50.05-12.31-8.56
EPS (Recurring)-0.88-1.37-1.04-0.55-0.36
EPS (Basic, Before Extraordinaries)-0.89-1.45-1.03-0.25-0.18
EPS (Diluted)-0.89-1.45-1.03-0.25-0.18
EBITDA-38.11-69.35-53.15-34.93-25.13
Non-Operating Income (Expense)5.623.882.181.230.92
Other After Tax Adjustments-0.000.000.000.00
Stock Option Compensation Expense2.164.530.871.751.74
Shares Outstanding49.2548.7448.7448.7448.74
Market Capitalization344.24344.24---

Income statement, quarterly

Currency USD, millions
Metric2026S1
Total Revenue0.00
Cost of Goods Sold Incl. D&A2.88
Gross Profit-2.88
Selling, General and Administrative Excl. Other38.11
Research and Development26.79
Other Operating Expense0.00
Operating Income-40.99
Interest Expense0.25
Unusual Expense0.51
Net Income Before Taxes-36.13
Income Taxes0.00
Consolidated Net Income-36.13
Net Income From Continuing Operations-36.13
Net Income-36.13
EPS (Recurring)-0.88
EPS (Basic, Before Extraordinaries)-0.89
EPS (Diluted)-0.89
EBITDA-38.11
Non-Operating Income (Expense)5.62
Stock Option Compensation Expense2.16
Shares Outstanding49.25
Market Capitalization344.24

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments136.84177.55135.2172.22
Short Term Receivables4.782.1918.723.55
Inventories0.000.000.000.00
Other Current Assets0.020.000.000.00
Total Current Assets141.64179.74153.9475.77
Net Property, Plant & Equipment1.862.061.770.07
Total Investments and Advances0.010.010.020.01
Intangible Assets33.7329.7431.7330.65
Other Assets3.272.131.731.28
Total Assets180.52213.68189.18107.79
Short Term Debt Incl. Current Port. of LT Debt0.290.281.5524.91
Accounts Payable0.000.000.000.00
Other Current Liabilities21.549.1710.476.80
Total Current Liabilities21.839.4512.0231.71
Long Term Debt1.181.321.590.04
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities---0.66
Other Liabilities3.778.168.284.67
Total Liabilities26.7818.9321.9037.08
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity153.74194.76167.2870.70
Total Shareholders Equity153.74194.76167.2870.70
Accumulated Minority Interest0.000.000.000.00
Total Equity153.74194.76167.2870.70
Total Liabilities & Stockholders Equity180.52213.68189.18107.79
Book Value Per Share3.154.003.431.45
Tangible Book Value Per Share2.463.392.780.82
Full-Time Employees62---
Price to Book Ratio1.13---
Return on Assets-35.81-24.85-8.29-
Return on Equity-40.51-27.65-10.35-
Return on Invested Capital-45.57-25.52-7.29-12.10
Quick Ratio6.4919.0212.802.39
Current Ratio6.4919.0212.802.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-36.13-70.59-50.05-12.31-8.56
Depreciation0.200.250.340.110.02
Other Funds (Non Cash)0.4611.490.44-18.16-10.08
Funds from Operations-35.47-58.85-49.27-31.04-21.41
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital0.570.46-1.394.451.48
Cash from Operating Activities-34.90-58.39-50.65-26.59-19.93
Capital Expenditures0.00-0.00-0.730.000.00
Net Assets From Acquisitions0.00-3.390.000.00-4.82
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments0.00-33.860.0043.24-42.04
Purchase of Investments0.00-33.860.000.00-42.04
Sale Or Maturity of Investments0.000.000.0043.240.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities0.00-37.25-0.7343.24-46.86
Cash Dividends Paid0.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.00
Change in Capital Stock192.750.00104.8485.8640.25
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock192.750.00104.8485.8640.25
Proceedsfrom Stock Options192.670.00104.8485.8640.25
Issuance or Reduction of Debt, Net0.000.000.000.00-0.58
Change in Long Term Debt0.000.000.000.00-
Issuance of Long Term Debt0.000.000.000.00-
Reduction of Long Term Debt0.000.000.000.00-
Net Financing Active Other Cash Flow0.000.000.000.01-0.09
Other Financing Activities Uses0.000.000.000.00-0.09
Cash from Financing Activities192.57-0.38104.6785.7639.55
Exchange Rate Effect-0.05-0.22--
Net Change in Cash157.67-95.9753.06102.42-27.24
Free Cash Flow--58.40-51.38-26.59-19.93
Deferred Taxes & Investment Tax Credit-0.000.00-0.67-2.80

Balance sheet, quarterly

Currency USD, millions
Metric2026S1
Cash & Short Term Investments288.09
Short Term Receivables0.00
Inventories0.00
Other Current Assets7.44
Total Current Assets295.52
Net Property, Plant & Equipment1.61
Total Investments and Advances0.01
Intangible Assets32.84
Other Assets2.63
Total Assets332.61
Short Term Debt Incl. Current Port. of LT Debt0.26
Accounts Payable13.54
Other Current Liabilities9.15
Total Current Liabilities22.95
Long Term Debt1.04
Other Liabilities5.22
Total Liabilities29.21
Non-Equity Reserves0.00
Preferred Stock - Carrying Value0.00
Common Equity303.40
Total Shareholders Equity303.40
Accumulated Minority Interest0.00
Total Equity303.40
Total Liabilities & Stockholders Equity332.61
Book Value Per Share6.16
Tangible Book Value Per Share5.49
Price to Book Ratio1.13
Return on Invested Capital-11.87
Quick Ratio12.88
Current Ratio12.88

Cash flow, quarterly

Currency USD, millions
Metric2026S1
Net Income-36.13
Depreciation0.20
Other Funds (Non Cash)0.46
Funds from Operations-35.47
Extraordinary Item0.00
Changes in Working Capital0.57
Cash from Operating Activities-34.90
Capital Expenditures0.00
Net Assets From Acquisitions0.00
Sale of Fixed Assets and Businesses0.00
Purchase or Sale of Investments0.00
Purchase of Investments0.00
Sale Or Maturity of Investments0.00
Other Uses0.00
Other Sources0.00
Cash from Investing Activities0.00
Cash Dividends Paid0.00
Preferred Dividends (Cash Flow)0.00
Change in Capital Stock192.75
Repurchase of Common Pref Stock0.00
Sale of Common Pref Stock192.75
Proceedsfrom Stock Options192.67
Issuance or Reduction of Debt, Net0.00
Change in Long Term Debt0.00
Issuance of Long Term Debt0.00
Reduction of Long Term Debt0.00
Net Financing Active Other Cash Flow0.00
Other Financing Activities Uses0.00
Cash from Financing Activities192.57
Net Change in Cash157.67

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.53%0.9M36.5M147.40K
2026-10-152.58%0.9M36.5M137.44K
2026-09-302.75%1.0M36.5M122.26K
2026-09-152.38%0.9M36.5M122.28K
2026-08-312.41%0.9M36.5M110.72K
2026-08-142.58%0.9M36.5M96.26K
2026-07-313.29%1.2M36.6M91.19K
2026-07-153.42%1.2M36.3M111.07K
2026-06-303.43%1.2M36.3M137.21K
2026-06-152.95%1.1M36.3M142.18K
2026-05-292.19%0.8M36.1M137.18K
2026-05-152.13%0.8M36.1M152.46K
2026-04-301.64%0.8M46.0M214.94K
2026-04-15-0.4M-224.23K
2026-03-31-0.3M-227.30K
2026-03-13-0.2M-240.70K
2026-02-27-0.2M-344.68K
2026-02-13-0.1M-636.12K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-153Initial statement of beneficial ownership of securities2026-09-11SEC
2026-09-153Initial statement of beneficial ownership of securities2026-09-11SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-10SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13GSEC
2026-05-06SCHEDULE 13GSEC
2026-04-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-24SEC
2026-04-2320-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-16SCHEDULE 13GSEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11103.50K100
2026-10399.97K700
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
EQT Fund Management S.a r.l.10.55%
Nantahala Capital Management, LLC6.44%
Sanofi5.65%
Redmile Group, LLC5.61%
TCG Crossover Management, LLC4.21%
FEDERATED HERMES, INC.3.32%
Casdin Capital, LLC3.18%
Andera Partners3.12%
FMR LLC2.96%
Aberdeen Group plc2.51%

Funds

Fund% owned
Federated Hermes Kaufmann Fund2.01%
Federated Hermes Kaufmann Small Cap Fund1.26%
Fidelity Growth Company Fund1.03%
abrdn Healthcare Investors0.75%
abrdn World Healthcare Fund0.64%
abrdn Life Sciences Investors0.35%
Fidelity Growth Company K6 Fund0.29%
Fidelity Series Growth Company Fund0.26%
ALPS Medical Breakthroughs ETF0.12%
Federated Hermes Kaufmann Fund II0.04%

OakChart. AGMB. Cached 15 minutes.